immune cell infiltration and immune-related genes in the tumor microenvironment

mutationdetection

The impact of chromosomal fusions on 3D genome folding and recombination in the germ line

The spatial folding of chromosomes inside the nucleus has regulatory effects on gene expression, yet the impact of genome reshuffling on this organization remains unclear. Here, we take advantage of chromosome conformation capture in combination with single-nucleotide polymorphism (SNP) genotyping and analysis of crossover events to study how the higher-order chromatin organization and recombination landscapes are affected by chromosomal fusions in the mammalian germ line.

We demonstrate that chromosomal fusions alter the nuclear architecture during meiosis, including an increased rate of heterologous interactions in primary spermatocytes, and alterations in both chromosome synapsis and axis length.

These disturbances in topology were associated with changes in genomic landscapes of recombination, resulting in detectable genomic footprints. Overall, we show that chromosomal fusions impact the dynamic genome topology of germ cells in two ways: (i) altering chromosomal nuclear occupancy and synapsis, and (ii) reshaping landscapes of recombination.

Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of HNSCC with or without HPV infection

Head and neck squamous cell carcinoma (HNSCC) are the sixth most common cancer type in the world. Human papillomavirus (HPV) infection is an emerging risk factor for HNSCC. Immune infiltration of HNSCC is linked to therapeutic results. This article aimed to decide whether variations in HPV status affect immune infiltration, molecular mechanism, and how these results vary in HNSCC patients.

We investigated the tumor-infiltrating immune cells (TIICs) and immune-related gene differences between HPV (+) and HPV (-) HNSCC. The gene expression quantification data of HNSCC and their clinical information were download from the TCGA database. Immune-related genes have been linked to the ImmPort platform.

After analyzed of 22 TIICs in the HNSCC tumor environment by CIBERSORT and further assessment, lower memory B cell and higher T cell regulatory were connected with better HPV (-) HNSCC outcome, higher activated memory CD4 T cell, higher T cell regulatory, and lower activated NK cell were linked with better HPV (+) result.

We finally got five forms of immune genes (CAMP, EDNRB, NTS, CXCL9, LHB) associated with HNSCC progression. Higher expressions of CAMP, EDNRB, and NTS were associated with increased overall survival in HPV (-) patients. Higher expression of CXCL9 and lower expression of LHB contributed to increased overall survival of HPV (+) patients.

There tend to be discrepancies in the cell structure of TIICs and immune-related genes in HPV (-) and HPV (+) HNSCC. These variances are typically too crucial for the therapeutic outcome of the patient and the development of the tumor. In specific, our sample established these candidate immune cells and immune-related genes as candidate reservoirs for further researches.

mutationdetection
mutationdetection

Tie2 kinase inhibitor

A5979-25 25 mg
EUR 477.6
Description: IC50: A reversible and selective inhibitor of Tie2 with IC50 of 0.25 M, whose selectivity is 200-fold higher than that of p38.

Tie2 kinase inhibitor

A5979-5 5 mg
EUR 199.2
Description: IC50: A reversible and selective inhibitor of Tie2 with IC50 of 0.25 M, whose selectivity is 200-fold higher than that of p38.

Tie2 kinase inhibitor

A5979-5.1 10 mM (in 1mL DMSO)
EUR 536.4
Description: IC50: A reversible and selective inhibitor of Tie2 with IC50 of 0.25 M, whose selectivity is 200-fold higher than that of p38.

Tie2 Kinase Inhibitor

B1338-25 each
EUR 907.2

Tie2 Kinase Inhibitor

B1338-5 each
EUR 314.4

Tie2 kinase inhibitor

E1KS1577 10mg
EUR 1849.2

K252A (Kinase inhibitor)

SIH-455-100UG 100 µg
EUR 157.2
Description: The substance K252A is a kinase inhibitor. It is nonomuraea longicatena and has a purity of ?98%. The pure substance is white solid which is soluble to 25 mM in DMSO.

K252A (Kinase inhibitor)

SIH-455-1MG 1 mg
EUR 358.8
Description: The substance K252A is a kinase inhibitor. It is nonomuraea longicatena and has a purity of ?98%. The pure substance is white solid which is soluble to 25 mM in DMSO.

K252B (Kinase inhibitor)

SIH-456-100UG 100 µg
EUR 218.4
Description: The substance K252B is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble in DMSO (1 mg/ml) or dimethyl formamide (1 mg/ml).

K252B (Kinase inhibitor)

SIH-456-1MG 1 mg
EUR 682.8
Description: The substance K252B is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble in DMSO (1 mg/ml) or dimethyl formamide (1 mg/ml).

MAPKII Kinase Inhibitor

abx076811-1mg 1 mg
EUR 376.8

Sorafenib (Raf-1 kinase inhibitor)

SIH-476-10MG 10 mg
EUR 145.2
Description: The substance Sorafenib is a raf-1 kinase inhibitor. It is synthetically produced and has a purity of >99%. The pure substance is off white powder which is soluble inDMSO (200mg/ml) or ethanol (3mg/ml).

Sorafenib (Raf-1 kinase inhibitor)

SIH-476-50MG 50 mg
EUR 346.8
Description: The substance Sorafenib is a raf-1 kinase inhibitor. It is synthetically produced and has a purity of >99%. The pure substance is off white powder which is soluble inDMSO (200mg/ml) or ethanol (3mg/ml).

Tyrosine kinase inhibitor

HY-10421 25mg
EUR 459.6

Dasatinib (Kinase inhibitor)

SIH-440-25MG 25 mg
EUR 238.8
Description: The substance Dasatinib is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is crystalline solid which is soluble in DMSO (200 mg/ml), ethanol (very poorly ), and water (very poorly ).

Dasatinib (Kinase inhibitor)

SIH-440-5MG 5 mg
EUR 160.8
Description: The substance Dasatinib is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is crystalline solid which is soluble in DMSO (200 mg/ml), ethanol (very poorly ), and water (very poorly ).

IKK-? Kinase Inhibitor II

1811-1 each
EUR 189.6

IKK-? Kinase Inhibitor II

1811-5 each
EUR 574.8

RIP2 kinase inhibitor 2

HY-19761 50mg
EUR 2539.2

PP1 (Src kinase inhibitor)

SIH-469-25MG 25 mg
EUR 742.8
Description: The substance PP1 is a src kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is tan solid which is soluble in DMSO (25 mg/ml), slightly soluble in 100% ethanol.

PP1 (Src kinase inhibitor)

SIH-469-5MG 5 mg
EUR 246
Description: The substance PP1 is a src kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is tan solid which is soluble in DMSO (25 mg/ml), slightly soluble in 100% ethanol.

PP2 (Src kinase inhibitor)

SIH-470-25MG 25 mg
EUR 884.4
Description: The substance PP2 is a src kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (25 mg/ml).

PP2 (Src kinase inhibitor)

SIH-470-5MG 5 mg
EUR 279.6
Description: The substance PP2 is a src kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (25 mg/ml).

C16 (PKR kinase inhibitor)

SIH-498-25MG 25 mg
EUR 420
Description: The substance C16 is a pkr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is solid which is soluble in DMSO 12 mg/ml .

C16 (PKR kinase inhibitor)

SIH-498-5MG 5 mg
EUR 164.4
Description: The substance C16 is a pkr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is solid which is soluble in DMSO 12 mg/ml .

Midostaurin (Kinase inhibitor)

SIH-468-1MG 1 mg
EUR 205.2
Description: The substance Midostaurin is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white powder which is soluble in DMSO (15 mg/ml), MDC (10 mg/ml), methanol (5 mg/ml) or 100% ethanol (2.5 mg/ml).

Midostaurin (Kinase inhibitor)

SIH-468-5MG 5 mg
EUR 608.4
Description: The substance Midostaurin is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white powder which is soluble in DMSO (15 mg/ml), MDC (10 mg/ml), methanol (5 mg/ml) or 100% ethanol (2.5 mg/ml).

Aurora Kinase Inhibitor 3

HY-112373 1mg
EUR 198

6BIO (PDK1 kinase inhibitor)

SIH-422-25MG 25 mg
EUR 474
Description: The substance 6BIO is a pdk1 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is dark red solid which is soluble to 10 mM in DMSO and to 10 mM in ethanol.

6BIO (PDK1 kinase inhibitor)

SIH-422-5MG 5 mg
EUR 178.8
Description: The substance 6BIO is a pdk1 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is dark red solid which is soluble to 10 mM in DMSO and to 10 mM in ethanol.

LYS6K2 (S6 kinase inhibitor)

SIH-462-25MG 25 mg
EUR 582
Description: The substance LYS6K2 is a s6 kinase inhibitor. It is synthetically produced and has a purity of 0.97. The pure substance is yellow solid which is soluble in DMSO (up to 1 mg/ml) or DMF (up to 3 mg/ml with warming).

LYS6K2 (S6 kinase inhibitor)

SIH-462-5MG 5 mg
EUR 205.2
Description: The substance LYS6K2 is a s6 kinase inhibitor. It is synthetically produced and has a purity of 0.97. The pure substance is yellow solid which is soluble in DMSO (up to 1 mg/ml) or DMF (up to 3 mg/ml with warming).

Aurora Kinase Inhibitor III

B7947-.5 500 µg
EUR 141.6
Description: Aurora Kinase Inhibitor III

Aurora Kinase Inhibitor III

B7947-1 1 mg
EUR 214.8
Description: Aurora Kinase Inhibitor III

Aurora Kinase Inhibitor III

B7947-5 5 mg
EUR 714
Description: Aurora Kinase Inhibitor III

KT5720 (PKA kinase inhibitor)

SIH-457-100UG 100 µg
EUR 246
Description: The substance KT5720 is a pka kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white powder which is soluble in methanol: clear colorless solution at 5 mg/ml.

KT5720 (PKA kinase inhibitor)

SIH-457-500UG 500 µg
EUR 682.8
Description: The substance KT5720 is a pka kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white powder which is soluble in methanol: clear colorless solution at 5 mg/ml.

ml167 (Clk4 kinase inhibitor)

SIH-505-25MG 25 mg
EUR 608.4
Description: The substance ml167 is a clk4 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white to gray to brown which is soluble in DMSO 10 mg/ml, clear .

ml167 (Clk4 kinase inhibitor)

SIH-505-5MG 5 mg
EUR 205.2
Description: The substance ml167 is a clk4 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white to gray to brown which is soluble in DMSO 10 mg/ml, clear .

GW2580 (cFMS kinase inhibitor)

SIH-449-25MG 25 mg
EUR 447.6
Description: The substance GW2580 is a cfms kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble in DMSO: 10 mg/ml, clear (warmed) .

GW2580 (cFMS kinase inhibitor)

SIH-449-5MG 5 mg
EUR 168
Description: The substance GW2580 is a cfms kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble in DMSO: 10 mg/ml, clear (warmed) .

PD98059 (MEK kinase inhibitor)

SIH-466-25MG 25 mg
EUR 514.8
Description: The substance PD98059 is a mek kinase inhibitor. It is synthetically produced and has a purity of ?95%. The pure substance is pale yellow solid which is soluble in DMSO (6.5 mg/ml); 25 mg/ml in anhydrous DMSO), methanol, dichlormethane and 100% ethanol (0.6 mg/ml).

PD98059 (MEK kinase inhibitor)

SIH-466-5MG 5 mg
EUR 184.8
Description: The substance PD98059 is a mek kinase inhibitor. It is synthetically produced and has a purity of ?95%. The pure substance is pale yellow solid which is soluble in DMSO (6.5 mg/ml); 25 mg/ml in anhydrous DMSO), methanol, dichlormethane and 100% ethanol (0.6 mg/ml).

AZD6244 (ERK kinase inhibitor)

SIH-495-25MG 25 mg
EUR 716.4
Description: The substance AZD6244 is a erk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in DMSO (92 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), and ethanol (<1 mg/ml at 25 °C).

AZD6244 (ERK kinase inhibitor)

SIH-495-5MG 5 mg
EUR 252
Description: The substance AZD6244 is a erk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in DMSO (92 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), and ethanol (<1 mg/ml at 25 °C).

SRPIN340 (SR kinase inhibitor)

SIH-514-25MG 25 mg
EUR 481.2
Description: The substance SRPIN340 is a sr kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is off-white solid which is soluble to 100 mM in DMSO and to 50 mM in 1eq. HCl.

SRPIN340 (SR kinase inhibitor)

SIH-514-5MG 5 mg
EUR 178.8
Description: The substance SRPIN340 is a sr kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is off-white solid which is soluble to 100 mM in DMSO and to 50 mM in 1eq. HCl.

AG1296 (PDGFR kinase inhibitor)

SIH-426-25MG 25 mg
EUR 608.4
Description: The substance AG1296 is a pdgfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white to brownish solid which is soluble in DMSO or dichloromethane.

AG1296 (PDGFR kinase inhibitor)

SIH-426-5MG 5 mg
EUR 205.2
Description: The substance AG1296 is a pdgfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white to brownish solid which is soluble in DMSO or dichloromethane.

SU1498 (VEGFR kinase inhibitor)

SIH-480-25MG 25 mg
EUR 447.6
Description: The substance SU1498 is a vegfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is solid which is soluble in DMSO .

SU1498 (VEGFR kinase inhibitor)

SIH-480-5MG 5 mg
EUR 169.2
Description: The substance SU1498 is a vegfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is solid which is soluble in DMSO .

PD325901 (MEK kinase inhibitor)

SIH-507-25MG 25 mg
EUR 554.4
Description: The substance PD325901 is a mek kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble to 25 mM in DMSO.

PD325901 (MEK kinase inhibitor)

SIH-507-5MG 5 mg
EUR 205.2
Description: The substance PD325901 is a mek kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble to 25 mM in DMSO.

PHA 665752 (MET kinase inhibitor)

SIH-421-25MG 25 mg
EUR 696
Description: The substance PHA 665752 is a met kinase inhibitor. It is synthetically produced and has a purity of >98. The pure substance is yellow solid which is soluble to 100 mM in DMSO. .

PHA 665752 (MET kinase inhibitor)

SIH-421-5MG 5 mg
EUR 231.6
Description: The substance PHA 665752 is a met kinase inhibitor. It is synthetically produced and has a purity of >98. The pure substance is yellow solid which is soluble to 100 mM in DMSO. .

A83 01 (ALK kinase inhibitor)

SIH-423-25MG 25 mg
EUR 514.8
Description: The substance A83 01 is a alk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige powder which is soluble to 50 mM in DMSO.

A83 01 (ALK kinase inhibitor)

SIH-423-5MG 5 mg
EUR 187.2
Description: The substance A83 01 is a alk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige powder which is soluble to 50 mM in DMSO.

CID 2011756 (PKD kinase inhibitor)

SIH-438-25MG 25 mg
EUR 514.8
Description: The substance CID 2011756 is a pkd kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble to 50 mM in DMSO.

CID 2011756 (PKD kinase inhibitor)

SIH-438-5MG 5 mg
EUR 184.8
Description: The substance CID 2011756 is a pkd kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble to 50 mM in DMSO.

KT 5823 (PKG kinase inhibitor)

SIH-458-100UG 100 µg
EUR 246
Description: The substance KT 5823 is a pkg kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble in DMSO (20 mg/ml), dimethyl formamide (20 mg/ml) and ethyl acetate (5 mg/ml).

KT 5823 (PKG kinase inhibitor)

SIH-458-500UG 500 µg
EUR 682.8
Description: The substance KT 5823 is a pkg kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble in DMSO (20 mg/ml), dimethyl formamide (20 mg/ml) and ethyl acetate (5 mg/ml).

NPC 15437 (PKC kinase inhibitor)

SIH-464-1MG 1 mg
EUR 205.2
Description: The substance NPC 15437 is a pkc kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in water, DMSO or methanol.

NPC 15437 (PKC kinase inhibitor)

SIH-464-5MG 5 mg
EUR 447.6
Description: The substance NPC 15437 is a pkc kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in water, DMSO or methanol.

Src I1 (Src kinase inhibitor)

SIH-478-25MG 25 mg
EUR 399.6
Description: The substance Src I1 is a src kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (5 mg/ml).

Src I1 (Src kinase inhibitor)

SIH-478-5MG 5 mg
EUR 158.4
Description: The substance Src I1 is a src kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (5 mg/ml).

GF109203X (PKC kinase inhibitor)

SIH-447-10MG 10 mg
EUR 306
Description: The substance GF109203X is a pkc kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is red solid which is soluble in dimethyl formamide or DMSO (10 mg/ml, warm to 40°C and vortex well).

GF109203X (PKC kinase inhibitor)

SIH-447-1MG 1 mg
EUR 178.8
Description: The substance GF109203X is a pkc kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is red solid which is soluble in dimethyl formamide or DMSO (10 mg/ml, warm to 40°C and vortex well).

Auranofin (IKK kinase inhibitor)

SIH-493-50MG 50 mg
EUR 178.8
Description: The substance Auranofin is a ikk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble in DMSO (5 mg/ml) or 100% ethanol (4 mg/ml).

LY364947 (ALK5 kinase inhibitor)

SIH-504-25MG 25 mg
EUR 474
Description: The substance LY364947 is a alk5 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow to brown solid which is soluble to 100 mM in DMSO.

LY364947 (ALK5 kinase inhibitor)

SIH-504-5MG 5 mg
EUR 184.8
Description: The substance LY364947 is a alk5 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow to brown solid which is soluble to 100 mM in DMSO.

p21/Cyclin-Dependent Kinase Inhibitor 1

MO47036 100 ul
EUR 418.8

AG 1478 (EGFR kinase inhibitor)

SIH-425-25MG 25 mg
EUR 474
Description: The substance AG 1478 is a egfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to light yellow solid which is soluble in DMSO (10 mg/ml).

AG 1478 (EGFR kinase inhibitor)

SIH-425-5MG 5 mg
EUR 184.8
Description: The substance AG 1478 is a egfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to light yellow solid which is soluble in DMSO (10 mg/ml).

AG 1517 (EGFR kinase inhibitor)

SIH-427-25MG 25 mg
EUR 541.2
Description: The substance AG 1517 is a egfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in DMSO.

AG 1517 (EGFR kinase inhibitor)

SIH-427-5MG 5 mg
EUR 192
Description: The substance AG 1517 is a egfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in DMSO.

AG 879 (NGFR kinase inhibitor)

SIH-429-25MG 25 mg
EUR 514.8
Description: The substance AG 879 is a ngfr kinase inhibitor. It is synthetically produced and has a purity of ?99%. The pure substance is yellow solid which is soluble in 100% ethanol (25 mg/ml) or DMSO (25 mg/ml).

AG 879 (NGFR kinase inhibitor)

SIH-429-5MG 5 mg
EUR 182.4
Description: The substance AG 879 is a ngfr kinase inhibitor. It is synthetically produced and has a purity of ?99%. The pure substance is yellow solid which is soluble in 100% ethanol (25 mg/ml) or DMSO (25 mg/ml).

Bml 277 (CHK2 kinase inhibitor)

SIH-436-10MG 10 mg
EUR 210
Description: The substance Bml 277 is a chk2 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (20 mg/ml) or ethanol (20 mg/ml).

Bml 277 (CHK2 kinase inhibitor)

SIH-436-50MG 50 mg
EUR 608.4
Description: The substance Bml 277 is a chk2 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (20 mg/ml) or ethanol (20 mg/ml).

GW 441756 (NGFR kinase inhibitor)

SIH-450-10MG 10 mg
EUR 279.6
Description: The substance GW 441756 is a ngfr kinase inhibitor. It is synthetically produced and has a purity of >99. The pure substance is red solid which is soluble to 15 mM in DMSO.

GW 441756 (NGFR kinase inhibitor)

SIH-450-50MG 50 mg
EUR 877.2
Description: The substance GW 441756 is a ngfr kinase inhibitor. It is synthetically produced and has a purity of >99. The pure substance is red solid which is soluble to 15 mM in DMSO.

LFM A13 (BTK kinase inhibitor)

SIH-461-25MG 25 mg
EUR 481.2
Description: The substance LFM A13 is a btk kinase inhibitor. It is synthetically produced and has a purity of ?97%. The pure substance is yellow solid which is soluble in DMSO (10 mg/ml) or ethanol (0.3 mg/ml).

LFM A13 (BTK kinase inhibitor)

SIH-461-5MG 5 mg
EUR 178.8
Description: The substance LFM A13 is a btk kinase inhibitor. It is synthetically produced and has a purity of ?97%. The pure substance is yellow solid which is soluble in DMSO (10 mg/ml) or ethanol (0.3 mg/ml).

Y 27632 (ROCK kinase inhibitor)

SIH-486-1MG 1 mg
EUR 178.8
Description: The substance Y 27632 is a rock kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to pale yellow powder which is soluble in DMSO (25 mg/ml), methanol (25 mg/ml), acetonitrile (<1 mg/ml), dioxan (<1 mg/ml), water (very soluble.

Y 27632 (ROCK kinase inhibitor)

SIH-486-5MG 5 mg
EUR 393.6
Description: The substance Y 27632 is a rock kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to pale yellow powder which is soluble in DMSO (25 mg/ml), methanol (25 mg/ml), acetonitrile (<1 mg/ml), dioxan (<1 mg/ml), water (very soluble.

AG 494 (EGFR kinase inhibitor)

SIH-491-10MG 10 mg
EUR 178.8
Description: The substance AG 494 is a egfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow solid which is soluble in DMSO (25 mg/ml) or 100% ethanol (25 mg/ml).

AG 494 (EGFR kinase inhibitor)

SIH-491-50MG 50 mg
EUR 481.2
Description: The substance AG 494 is a egfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow solid which is soluble in DMSO (25 mg/ml) or 100% ethanol (25 mg/ml).

SR 3576 (JNK3 kinase inhibitor)

SIH-513-5MG 5 mg
EUR 298.8
Description: The substance SR 3576 is a jnk3 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off white solid which is soluble to 100 mM in DMSO.

CHIR99021 (GSK3? kinase inhibitor)

SIH-437-1MG 1 mg
EUR 151.2
Description: The substance CHIR99021 is a gsk3? kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to light brown solid which is soluble to 20 mM in DMSO.

CHIR99021 (GSK3? kinase inhibitor)

SIH-437-5MG 5 mg
EUR 246
Description: The substance CHIR99021 is a gsk3? kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to light brown solid which is soluble to 20 mM in DMSO.

Gefitinib (EGFR Kinase inhibitor)

SIH-445-250MG 250 mg
EUR 360
Description: The substance Gefitinib is a egfr kinase inhibitor. It is synthetically produced and has a purity of >99%. The pure substance is solid which is soluble in DMSO (89 mg/ml at 25 °C), methanol (20 mg/ml), ethanol (4 mg/ml at 25 °C), DMF (20 mg/ml), and water (<1 mg/ml at 25 °C).

Gefitinib (EGFR Kinase inhibitor)

SIH-445-50MG 50 mg
EUR 164.4
Description: The substance Gefitinib is a egfr kinase inhibitor. It is synthetically produced and has a purity of >99%. The pure substance is solid which is soluble in DMSO (89 mg/ml at 25 °C), methanol (20 mg/ml), ethanol (4 mg/ml at 25 °C), DMF (20 mg/ml), and water (<1 mg/ml at 25 °C).

Axitinib (VEGFR kinase inhibitor)

SIH-494-10MG 10 mg
EUR 346.8
Description: The substance Axitinib is a vegfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to tan powder which is soluble to 25 mM in DMSO.

Casein Kinase II Inhibitor IV

HY-111378 10mM/1mL
EUR 590.4

STO 609 (CAMKK kinase inhibitor)

SIH-479-25MG 25 mg
EUR 474
Description: The substance STO 609 is a camkk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow solid which is soluble in DMSO (10 mg/ml).

STO 609 (CAMKK kinase inhibitor)

SIH-479-5MG 5 mg
EUR 181.2
Description: The substance STO 609 is a camkk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow solid which is soluble in DMSO (10 mg/ml).

ZM 306416 (VEGFR kinase inhibitor)

SIH-487-25MG 25 mg
EUR 474
Description: The substance ZM 306416 is a vegfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (3 mg/ml) or ethanol (1 mg/ml).

ZM 306416 (VEGFR kinase inhibitor)

SIH-487-5MG 5 mg
EUR 178.8
Description: The substance ZM 306416 is a vegfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (3 mg/ml) or ethanol (1 mg/ml).

Ruxolitinib (JAK kinase inhibitor)

SIH-509-25MG 25 mg
EUR 750
Description: The substance Ruxolitinib is a jak kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is off-white solid which is soluble in DMSO (25 mg/ml) or EtOH (~15 mg/ml).

Ruxolitinib (JAK kinase inhibitor)

SIH-509-5MG 5 mg
EUR 285.6
Description: The substance Ruxolitinib is a jak kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is off-white solid which is soluble in DMSO (25 mg/ml) or EtOH (~15 mg/ml).

AG490 (JAK-2 kinase inhibitor)

SIH-428-25MG 25 mg
EUR 339.6
Description: The substance AG490 is a jak-2 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is tan solid which is soluble in DMSO (30 mg/ml), dimethyl formamide (40 mg/ml) or 100% ethanol (10 mg/ml).

AG490 (JAK-2 kinase inhibitor)

SIH-428-5MG 5 mg
EUR 158.4
Description: The substance AG490 is a jak-2 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is tan solid which is soluble in DMSO (30 mg/ml), dimethyl formamide (40 mg/ml) or 100% ethanol (10 mg/ml).

WHI P131 (JAK3 kinase inhibitor)

SIH-485-10MG 10 mg
EUR 178.8
Description: The substance WHI P131 is a jak3 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in DMSO (~1 mg/ml), and DMF (~1 mg/ml).

WHI P131 (JAK3 kinase inhibitor)

SIH-485-50MG 50 mg
EUR 460.8
Description: The substance WHI P131 is a jak3 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in DMSO (~1 mg/ml), and DMF (~1 mg/ml).

Apigenin (Protein kinase inhibitor)

SIH-249-10MG 10 mg
EUR 127.2
Description: The substance Apigenin is a protein kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is white solid which is soluble to 50 mM in DMSO.

Apigenin (Protein kinase inhibitor)

SIH-249-50MG 50 mg
EUR 255.6
Description: The substance Apigenin is a protein kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is white solid which is soluble to 50 mM in DMSO.

ATM Kinase Inhibitor, KU-55933

1685-5 each
EUR 288

Diacylglycerol Kinase Inhibitor I

50R-R59022 50 mg
EUR 289.2
Description: Diacylglycerol Kinase Inhibitor I chemical reference substance

Adenosine Kinase Inhibitor (hydrate)

C5282-1 1 mg
EUR 134.4
Description: IC50: 1.7 nM in cell-free assaysAdenosine Kinase Inhibitor is an inhibitor of adenosine kinase. Adenosine kinase is the key metabolizing enzyme regulating cellular adenosine concentrations.

Adenosine Kinase Inhibitor (hydrate)

C5282-10 10 mg
EUR 435.6
Description: IC50: 1.7 nM in cell-free assaysAdenosine Kinase Inhibitor is an inhibitor of adenosine kinase. Adenosine kinase is the key metabolizing enzyme regulating cellular adenosine concentrations.

Adenosine Kinase Inhibitor (hydrate)

C5282-5 5 mg
EUR 360
Description: IC50: 1.7 nM in cell-free assaysAdenosine Kinase Inhibitor is an inhibitor of adenosine kinase. Adenosine kinase is the key metabolizing enzyme regulating cellular adenosine concentrations.

Dorsomorphin (AMPK kinase inhibitor)

SIH-443-25MG 25 mg
EUR 514.8
Description: The substance Dorsomorphin is a ampk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow solid which is soluble in DMSO (4 mg/ml, warm).

Dorsomorphin (AMPK kinase inhibitor)

SIH-443-5MG 5 mg
EUR 184.8
Description: The substance Dorsomorphin is a ampk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow solid which is soluble in DMSO (4 mg/ml, warm).

Imatinib mesylate (Kinase inhibitor)

SIH-453-100MG 100 mg
EUR 279.6
Description: The substance Imatinib mesylate is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble H2O: soluble10 mg/ml, clear .

Imatinib mesylate (Kinase inhibitor)

SIH-453-20MG 20 mg
EUR 151.2
Description: The substance Imatinib mesylate is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble H2O: soluble10 mg/ml, clear .

LY 294002 (PI 3-Kinase inhibitor)

SIH-252-25MG 25 mg
EUR 532.8
Description: The substance LY 294002 is a pi 3-kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is white crystalline solid which is soluble to 5 mM in ethanol and to 25 mM in DMSO.

LY 294002 (PI 3-Kinase inhibitor)

SIH-252-5MG 5 mg
EUR 190.8
Description: The substance LY 294002 is a pi 3-kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is white crystalline solid which is soluble to 5 mM in ethanol and to 25 mM in DMSO.

BAY 11 7082 (IKK kinase inhibitor)

SIH-434-10MG 10 mg
EUR 184.8
Description: The substance BAY 11 7082 is a ikk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble to 25 mM in ethanol and to 100 mM in DMSO.

BAY 11 7082 (IKK kinase inhibitor)

SIH-434-50MG 50 mg
EUR 507.6
Description: The substance BAY 11 7082 is a ikk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble to 25 mM in ethanol and to 100 mM in DMSO.

PX 866 (PI 3-Kinase inhibitor)

SIH-471-1MG 1 mg
EUR 178.8
Description: The substance PX 866 is a pi 3-kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is crystalline solid which is soluble in DMSO at 200 mg/ml; soluble in ethanol at 200 mg/ml; very poorly soluble in water.

Multi-ancestry genome-wide association study identifies 27 loci associated with measures of hemolysis following blood storage

The evolutionary pressure of endemic malaria and other erythrocytic pathogens has shaped variation in genes encoding erythrocyte structural and functional proteins, influencing responses to hemolytic stress during transfusion and disease.

We sought to identify such genetic variants in blood donors by conducting a genome-wide association study (GWAS) of 12,353 volunteer donors, including 1,483 African Americans, 1,477 Asians, and 960 Hispanics, whose stored erythrocytes were characterized by quantitative assays of in vitro osmotic, oxidative, and cold-storage hemolysis.

GWAS revealed 27 significant loci (p<5×10-8), many in candidate genes known to modulate erythrocyte structure, metabolism, and ion channels, including SPTA1, ALDH2, ANK1, HK1, MAPKAPK5, AQP1, PIEZO1, and SLC4A1/Band 3. GWAS of oxidative hemolysis identified variants in antioxidant enzymes including GLRX, GPX4, G6PD, and a novel golgi-transport protein SEC14L4.

Genome wide significant loci were also tested for association with the severity of steady state (baseline) in vivo hemolytic anemia in patients with sickle cell disease, with confirmation of identified SNPs in HBA2, G6PD, PIEZO1, AQP1 and SEC14L4. Many of the identified variants, such as those in G6PD, have previously been shown to impair erythrocyte recovery after transfusion, associate with anemia, or cause rare Mendelian human hemolytic diseases.

Candidate SNPs in these genes, especially in polygenic combinations, may affect RBC recovery after transfusion and modulate disease severity in hemolytic diseases, such as sickle cell disease and malaria.

Incorporating Genomic and Genetic Testing into the Treatment of Metastatic Luminal Breast Cancer

Background: Treatment of patients with luminal metastatic breast cancer (MBC) has become even more complex over the last few years as molecular profiling has begun to alter disease management. It is well accepted that MBC is not curable but is treatable. Today we are able to prolong progression-free survival and partly overall survival with targeted and more individual treatment strategies adjusted according to the molecular subtype.

Summary: Genetic and genomic testing has become therapeutically relevant in luminal MBC and is therefore an integral component within the treatment spectrum. By now, germline testing of BRCABRCAPIK3CA mutations are inevitable elements in disease management and the current state of the art in luminal MBC patients.

Furthermore, testing of ESR1 resistance mutation, ERBB2 mutation, microsatellite instability, and neurotrophic tyrosine receptor kinase (NTRK) gene fusion (mainly in secretory breast cancer) has recently gained increasing attention. However, based on the expanding role of personalized medicine, clinicians are now faced with substantial new challenges and possibly unsuspected possibilities. The following review summarizes current developments in genetic and genomic testing in luminal MBC.

 

Key messages: In luminal MBC genomics have become an integral component within the spectrum of oncological treatment establishing novel therapeutic facilities. Further developments in treatment personalization adjusted according to the molecular subtype should become increasingly important in order to enhance the progress of de-escalation of chemotherapy in luminal MBC. However, based on the expanding role of personalized medicine, clinicians are now faced with substantial new challenges and possibly unsuspected possibilities.

HIV-P24 antigen array kit

VArk-Lsx001 unit Ask for price
Description: Fourth-generation HIV immunoassays detect viral p24 protein in the blood.

HIV-1 p17-p24 recombinant antigen.

00172-V-100ugvial 100ug/vial
EUR 150
Description: HIV-1 p17-p24 recombinant antigen.

HIV-1 GAG P24 Recombinant Antigen

00111-V-01mg 0,1 mg
EUR 321
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa

HIV-1 GAG P24 Recombinant Antigen

00111-V-1000ug 1000 ug
EUR 1539
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa

HIV 1 p24 core recombinant antigen

00177-V-01mg 0,1 mg
EUR 321
Description: HIV 1 p24 core recombinant antigen.

HIV 1 p24 core recombinant antigen

00177-V-1000ug 1000 ug
EUR 1539
Description: HIV 1 p24 core recombinant antigen.

HIV 1 p24 core recombinant antigen.

00177-V-100ugvial 100ug/vial
EUR 150
Description: HIV 1 p24 core recombinant antigen.

HIV Type 1 p24 Antigen ELISA (5 X 96 Determinations)

0801200 5 X 96T
EUR 2563

HIV Type 1 p24 Antigen ELISA (5 X 96 Determinations)

801200 5 X 96 Determinations
EUR 2330

HIV Type 1 p24 Antigen ELISA 2.0 (5 X 96 Determinations)

801008 5 X 96 Determinations
EUR 2386

HIV Type 1 p24 Antigen ELISA 2.0 (5 X 96 Determinations)

0801008 5 X 96T
EUR 2505

Human HIV(1+2 antibodies plus p24 antigen (4th Generation) ELISA Kit

EH4101 96T
EUR 571.5
Description: Method of detection: Qualitative ;Reacts with: Homo sapiens;Sensitivity: Qualitative

HIV-1 p24 ELISA Kit

Z7040001 1 kit
EUR 752

HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa

00111-V-100ugvial 100ug/vial
EUR 150
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa

HIV-1 p17/24/gp120 antigen

00169-V-01mg 0,1 mg
EUR 321
Description: HIV-1 p17/24/gp120 antigen.The protein contains the HIV immunodominant regions from gag p17-p24 gp 120.

HIV-1 p17/24/gp120 antigen

00169-V-1000ug 1000 ug
EUR 1539
Description: HIV-1 p17/24/gp120 antigen.The protein contains the HIV immunodominant regions from gag p17-p24 gp 120.

HIV-1 intergase antigen

00199-V-01mg 0,1 mg
EUR 321
Description: HIV-1 intergase antigen. The protein contains the HIV-1 immunodominant regions from pol protein (integrase).

HIV-1 intergase antigen

00199-V-1000ug 1000 ug
EUR 1539
Description: HIV-1 intergase antigen. The protein contains the HIV-1 immunodominant regions from pol protein (integrase).

HIV-1 p24 Antibody

7313-002mg 0.02 mg
EUR 206.18
Description: HIV-1 p24 Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix. The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein. The p24 is the major capsid protein of the virus and has been used in clinical trials as one of the components of the HIV-1 vaccine because of the high degree of sequence conservation between different strains.

HIV-1 p24 Antibody

7313-01mg 0.1 mg
EUR 523.7
Description: HIV-1 p24 Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix. The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein. The p24 is the major capsid protein of the virus and has been used in clinical trials as one of the components of the HIV-1 vaccine because of the high degree of sequence conservation between different strains.

HIV-1 p24 Antibody

abx023027-1ml 1 ml
EUR 693.6

HIV-1 p24 Antibody

abx023925-1mg 1 mg
EUR 828

HIV-1 p24 Antibody

abx023926-1mg 1 mg
EUR 828

HIV-1 p24 Antibody

abx021869-1mg 1 mg
EUR 794.4

HIV-1 p24 Antibody

abx021870-1mg 1 mg
EUR 760.8

HIV-1 p24 Antibody

abx021871-1mg 1 mg
EUR 794.4

HIV-1 p24 Antibody

abx021872-1mg 1 mg
EUR 794.4

HIV-1 p24 Antibody

abx021873-1mg 1 mg
EUR 794.4

HIV-1 p24 Antibody

abx021882-1mg 1 mg
EUR 1178.4

HIV-1 p24 Antibody

abx021883-1mg 1 mg
EUR 1220.4

HIV-1 p24 Antibody

abx021886-1mg 1 mg
EUR 1220.4

HIV-1 p24 Antibody

abx021887-1mg 1 mg
EUR 1220.4

HIV-1 p24 Antibody

abx021888-1mg 1 mg
EUR 1220.4

HIV-1 p24 Antibody

20-abx137062
  • EUR 427.20
  • EUR 627.60
  • 0.5 mg
  • 1 mg

HIV-1 p24

E5-00024 1mg
EUR 1152

HIV-1 p24

E62H002 100ug
EUR 458.4

HIV-1 tat recombinant antigen

00110-V-01mg 0,1 mg
EUR 321
Description: HIV-1 tat recombinant antigen full length 15 kDa

HIV-1 tat recombinant antigen

00110-V-1000ug 1000 ug
EUR 1539
Description: HIV-1 tat recombinant antigen full length 15 kDa

HIV-1 nef recombinant antigen

00112-V-01mg 0,1 mg
EUR 321
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa

HIV-1 nef recombinant antigen

00112-V-1000ug 1000 ug
EUR 1539
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa

HIV-1 gag recombinant antigen

8934 100 ug
EUR 542.86
Description: This is HIV-1 gag recombinant antigen for ELISA,WB.

HIV-1 nef recombinant antigen

8941 100 ug
EUR 477.6
Description: This is HIV-1 nef recombinant antigen for ELISA,WB.

HIV-1 gp41 recombinant antigen,

00170-V-01mg 0,1 mg
EUR 321
Description: HIV-1 gp41 recombinant antigen.

HIV-1 gp41 recombinant antigen,

00170-V-1000ug 1000 ug
EUR 1539
Description: HIV-1 gp41 recombinant antigen.

HIV-1 gp41 recombinant antigen

8908 100 ug
EUR 673.36
Description: This is HIV-1 gp41 recombinant antigen for ELISA,WB.

HIV-1 gp41 recombinant antigen

8933 100 ug
EUR 477.6
Description: This is HIV-1 gp41 recombinant antigen for ELISA,WB.

HIV-1 gp41 recombinant antigen

9000 100 ug
EUR 484.13
Description: This is HIV-1 gp41 recombinant antigen for ELISA,WB.

HIV-1 gp41 recombinant antigen

9001 100 ug
EUR 484.13
Description: This is HIV-1 gp41 recombinant antigen for ELISA,WB.

HIV-1 gp41 recombinant antigen.

00170-V-100ugvial 100ug/vial
EUR 150
Description: HIV-1 gp41 recombinant antigen.

HIV p24 Antibody

abx021867-1mg 1 mg
EUR 1612.8

HIV p24 Antibody

abx021868-1mg 1 mg
EUR 1612.8

HIV-1 p17/24/gp120-gp41 recombinant antigen,

00168-V-01mg 0,1 mg
EUR 321
Description: HIV-1 p17/24/gp120-gp41 recombinant antigen.

HIV-1 p17/24/gp120-gp41 recombinant antigen,

00168-V-1000ug 1000 ug
EUR 1539
Description: HIV-1 p17/24/gp120-gp41 recombinant antigen.

HIV-1 p17/24/gp120-gp41 recombinant antigen.

00168-V-100ugvial 100ug/vial
EUR 150
Description: HIV-1 p17/24/gp120-gp41 recombinant antigen.

HIV 1 envelope recombinant antigen

00176-V-01mg 0,1 mg
EUR 321
Description: HIV 1 envelope recombinant antigen. HIV-1 evnelope protein spanning the C-Terminus of gp 120 and most of gp 41.

HIV 1 envelope recombinant antigen

00176-V-1000ug 1000 ug
EUR 1539
Description: HIV 1 envelope recombinant antigen. HIV-1 evnelope protein spanning the C-Terminus of gp 120 and most of gp 41.

ToX Antigen (P24,GRA1)

E61Y00305 1mg
EUR 840

HIV-1 env gp41 recombinant antigen

00113-V-01mg 0,1 mg
EUR 321
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa

HIV-1 env gp41 recombinant antigen

00113-V-1000ug 1000 ug
EUR 1539
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa

HIV-1 p24 Antibody (HRP)

abx023029-1ml 1 ml
EUR 886.8

HIV-1 p24 Antibody [8G9]

PM-6335-002mg 0.02 mg
EUR 206.18
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV-1 p24 Antibody [8G9]

PM-6335-01mg 0.1 mg
EUR 523.7
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV-1 p24 Antibody [7F4]

PM-6585-002mg 0.02 mg
EUR 206.18
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV-1 p24 Antibody [7F4]

PM-6585-01mg 0.1 mg
EUR 523.7
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV-1 p24 Antibody (FITC)

abx023026-1ml 1 ml
EUR 678

HIV-1 p24 Antibody (FITC)

abx021884-100ug 100 ug
EUR 886.8

HIV 1 / 2 p24 Antibody

abx021866-1mg 1 mg
EUR 1212

HIV 1 / 2 p24 Antibody

abx021890-1mg 1 mg
EUR 1212

HIV-1 gp41 Long recombinant antigen,

00171-V-01mg 0,1 mg
EUR 321
Description: HIV-1 gp41 Long recombinant antigen.

HIV-1 gp41 Long recombinant antigen,

00171-V-1000ug 1000 ug
EUR 1539
Description: HIV-1 gp41 Long recombinant antigen.

HIV-1 gp41 Long recombinant antigen.

00171-V-100ugvial 100ug/vial
EUR 150
Description: HIV-1 gp41 Long recombinant antigen.

HIV-1 p24 Antibody (Biotin)

abx023028-1ml 1 ml
EUR 794.4

Polyclonal HIV-1 p24 Antibody

APR11116G 0.1 mg
EUR 790.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human HIV-1 p24 . This antibody is tested and proven to work in the following applications:

HIV-1 p24 Protein

abx169032-1mg 1 mg
EUR 661.2

HIV-1 p24 Protein

abx061424-05mg 0.5 mg
EUR 886.8

HIV-1, p24 Protein

abx069857-1mg 1 mg
EUR 1888.8

HIV-1 p24 Protein

20-abx261886
  • EUR 5388.00
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

HIV-1 Gag p24

05-005 50 ug
EUR 434.4
Description: The HIV-1 Gag p24 is available in Europe and for worldwide shipping via Gentaur.

HIV-1 Gag p24

05-006 250 ug
EUR 1154.4
Description: The HIV-1 Gag p24 is available in Europe and for worldwide shipping via Gentaur.

Recombinant HIV-1 p24

7-07603 100µg Ask for price

Recombinant HIV-1 p24

7-07604 500µg Ask for price

Recombinant HIV-1 p24

7-07605 1000µg Ask for price

HIV 1 p24 Protein

abx060589-1mg 1 mg
EUR 1545.6

HIV-1 p17/24/gp120 antigen.The protein contains the HIV immunodominant regions from gag p17-p24 gp 120.

00169-V-100ugvial 100ug/vial
EUR 150
Description: HIV-1 p17/24/gp120 antigen.The protein contains the HIV immunodominant regions from gag p17-p24 gp 120.

HIV 1, 2 envelope recombinant antigen

00175-V-01mg 0,1 mg
EUR 321
Description: HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide.

HIV 1, 2 envelope recombinant antigen

00175-V-1000ug 1000 ug
EUR 1539
Description: HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide.

HIV-1 reverse transcriptase recombinant antigen

00198-V-01mg 0,1 mg
EUR 321
Description: HIV-1 reverse transcriptase recombinant antigen.

HIV-1 reverse transcriptase recombinant antigen

00198-V-1000ug 1000 ug
EUR 1539
Description: HIV-1 reverse transcriptase recombinant antigen.

HIV-1 reverse transcriptase recombinant antigen.

00198-V-100ugvial 100ug/vial
EUR 150
Description: HIV-1 reverse transcriptase recombinant antigen.

Feline Immunodeficiency Virus p24 Antigen (FIV p24) Antibody

abx411336-02mg 0.2 mg
EUR 710.4

Feline Immunodeficiency Virus p24 Antigen (FIV p24) Antibody

abx412988-2ml 2 ml
EUR 727.2

HIV Type-1 p24 Antibody

V2344-100UG 100 ug
EUR 349.3
Description: Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immune deficiency syndrome (AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic infections. HIV mainly infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages and dendritic cells. Two species of HIV infect humans: HIV-1 and HIV-2, with HIV-1 being the more virulent strain. The gag gene of human immunodeficiency virus 1 (HIV-1) encodes a precursor protein known as Pr55Gag. The viral protease PR cleaves this precursor to generate p17, p24, p7, and p6 proteins, which are required for virus particle assembly. HIV-1 Gag p24 is a capsid protein that constitutes the core of AIDS virus HIV-1. p6 and p7 are the components of the nucleocapsid, and p17 provides a protective matrix. HIV-1 Gag p24 is indispensable to the reproduction of AIDS virus and constitutes an essential element for the AIDS virus particle construction. As this protein is detectable from the early stage of AIDS virus infection, its measurement is commonly used as an indicator of HIV-1 infection and viral load.

HIV Type-1 p24 Antibody

V2344-20UG 20 ug
EUR 153.3
Description: Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immune deficiency syndrome (AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic infections. HIV mainly infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages and dendritic cells. Two species of HIV infect humans: HIV-1 and HIV-2, with HIV-1 being the more virulent strain. The gag gene of human immunodeficiency virus 1 (HIV-1) encodes a precursor protein known as Pr55Gag. The viral protease PR cleaves this precursor to generate p17, p24, p7, and p6 proteins, which are required for virus particle assembly. HIV-1 Gag p24 is a capsid protein that constitutes the core of AIDS virus HIV-1. p6 and p7 are the components of the nucleocapsid, and p17 provides a protective matrix. HIV-1 Gag p24 is indispensable to the reproduction of AIDS virus and constitutes an essential element for the AIDS virus particle construction. As this protein is detectable from the early stage of AIDS virus infection, its measurement is commonly used as an indicator of HIV-1 infection and viral load.

HIV Type-1 p24 Antibody

V2344CF488-100T 100 Tests
EUR 349.3
Description: Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immune deficiency syndrome (AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic infections. HIV mainly infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages and dendritic cells. Two species of HIV infect humans: HIV-1 and HIV-2, with HIV-1 being the more virulent strain. The gag gene of human immunodeficiency virus 1 (HIV-1) encodes a precursor protein known as Pr55Gag. The viral protease PR cleaves this precursor to generate p17, p24, p7, and p6 proteins, which are required for virus particle assembly. HIV-1 Gag p24 is a capsid protein that constitutes the core of AIDS virus HIV-1. p6 and p7 are the components of the nucleocapsid, and p17 provides a protective matrix. HIV-1 Gag p24 is indispensable to the reproduction of AIDS virus and constitutes an essential element for the AIDS virus particle construction. As this protein is detectable from the early stage of AIDS virus infection, its measurement is commonly used as an indicator of HIV-1 infection and viral load.

HIV Type-1 p24 Antibody

V2344SAF-100UG 100 ug
EUR 349.3
Description: Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immune deficiency syndrome (AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic infections. HIV mainly infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages and dendritic cells. Two species of HIV infect humans: HIV-1 and HIV-2, with HIV-1 being the more virulent strain. The gag gene of human immunodeficiency virus 1 (HIV-1) encodes a precursor protein known as Pr55Gag. The viral protease PR cleaves this precursor to generate p17, p24, p7, and p6 proteins, which are required for virus particle assembly. HIV-1 Gag p24 is a capsid protein that constitutes the core of AIDS virus HIV-1. p6 and p7 are the components of the nucleocapsid, and p17 provides a protective matrix. HIV-1 Gag p24 is indispensable to the reproduction of AIDS virus and constitutes an essential element for the AIDS virus particle construction. As this protein is detectable from the early stage of AIDS virus infection, its measurement is commonly used as an indicator of HIV-1 infection and viral load.

HIV-2 gp32 recombinant antigen

00173-V-01mg 0,1 mg
EUR 321
Description: HIV-2 gp32 recombinant antigen. .

HIV-2 gp32 recombinant antigen

00173-V-1000ug 1000 ug
EUR 1539
Description: HIV-2 gp32 recombinant antigen. .

HIV-2 gp36 recombinant antigen

8911 100 ug
EUR 673.36
Description: This is HIV-2 gp36 recombinant antigen for ELISA,WB.

HIV-2 gp36 recombinant antigen

8949 100 ug
EUR 529.8
Description: This is HIV-2 gp36 recombinant antigen for ELISA,WB.

HIV-2 gp36 recombinant antigen

9003 100 ug
EUR 484.13
Description: This is HIV-2 gp36 recombinant antigen for ELISA,WB.

HIV-2 gp32 recombinant antigen. .

00173-V-100ugvial 100ug/vial
EUR 150
Description: HIV-2 gp32 recombinant antigen. .

HIV type 1 P24

DAG1520 100 µg
EUR 972

HIV-1 p24 Antibody [8G9] (HRP)

PM-6335-HRP-002mg 0.02 mg
EUR 206.18
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV-1 p24 Antibody [8G9] (HRP)

PM-6335-HRP-01mg 0.1 mg
EUR 523.7
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV-1 p24 Antibody [7F4] (HRP)

PM-6585-HRP-002mg 0.02 mg
EUR 206.18
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV-1 p24 Antibody [7F4] (HRP)

PM-6585-HRP-01mg 0.1 mg
EUR 523.7
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV-1 p24 Antibody [8G9] (biotin)

PM-6335-biotin-002mg 0.02 mg
EUR 206.18
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV-1 p24 Antibody [8G9] (biotin)

PM-6335-biotin-01mg 0.1 mg
EUR 523.7
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV-1 p24 Antibody [7F4] (biotin)

PM-6585-biotin-002mg 0.02 mg
EUR 206.18
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV-1 p24 Antibody [7F4] (biotin)

PM-6585-biotin-01mg 0.1 mg
EUR 523.7
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV type O envelope antigen

00178-V-01mg 0,1 mg
EUR 321
Description: HIV type O envelope antigen. Synthetic HIV type-O peptide, containing the HIV type-O envelope-derived sequence.

HIV type O envelope antigen

00178-V-1000ug 1000 ug
EUR 1539
Description: HIV type O envelope antigen. Synthetic HIV type-O peptide, containing the HIV type-O envelope-derived sequence.

HIV 2 gp36 envelope antigen

00180-V-01mg 0,1 mg
EUR 321
Description: HIV 2 gp36 envelope antigen. Synthetic HIV-2 Peptide containing the HIV-2 specific sequence of gp36.

HIV 2 gp36 envelope antigen

00180-V-1000ug 1000 ug
EUR 1539
Description: HIV 2 gp36 envelope antigen. Synthetic HIV-2 Peptide containing the HIV-2 specific sequence of gp36.

Polyclonal HIV-1 p24 Antibody [7F4]

APR11117G 0.1 mg
EUR 790.8
Description: A polyclonal antibody raised in Mouse that recognizes and binds to Human HIV-1 p24 [7F4] . This antibody is tested and proven to work in the following applications:

HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide.

00175-V-100ugvial 100ug/vial
EUR 150
Description: HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide.

HIV-2 GP 36 Recombinant Antigen

00114-V-01mg 0,1 mg
EUR 321
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa

HIV-2 GP 36 Recombinant Antigen

00114-V-1000ug 1000 ug
EUR 1539
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa

HIV-1 p24, His tag

E410A26-20 20μg
EUR 520.8

HIV-1 p24 Core Protein

20-abx260141
  • EUR 1062.00
  • EUR 410.40
  • EUR 1646.40
  • 0.5 mg
  • 100 ug
  • 1 mg

Mouse antibody for HIV-1 p24

1941 100 ug
EUR 399.3
Description: This is purified Mouse monoclonal antibody against HIV-1 p24 for WB, ELISA.

Mouse antibody for HIV-1 p24

1946 100 ug
EUR 425.4
Description: This is purified Mouse monoclonal antibody against HIV-1 p24 for WB, ELISA.

Mouse antibody for HIV-1 p24

1947 100 ug
EUR 425.4
Description: This is purified Mouse monoclonal antibody against HIV-1 p24 for WB, ELISA.

Mouse antibody for HIV-1 p24

1948 100 ug
EUR 425.4
Description: This is purified Mouse monoclonal antibody against HIV-1 p24 for WB, ELISA.

Mouse antibody for HIV-1 p24

1949 100 ug
EUR 425.4
Description: This is purified Mouse monoclonal antibody against HIV-1 p24 for WB, ELISA.

QuickTiter HIV Lentivirus Quantitation Kit (p24 ELISA)

VPK-108-H 96 assays
EUR 866.4
Description: Quantitation of the HIV-1 p24 core protein of a lentiviral vector is an efficient, well-published method for determining lentivirus physical titer. The QuickTiter Lentivirus Quantitation Kits provide a convenient method of p24 antigen quantitation.

QuickTiter HIV Lentivirus Quantitation Kit (p24 ELISA)

VPK-108-H-5 5 x 96 assays
EUR 3560.4
Description: Quantitation of the HIV-1 p24 core protein of a lentiviral vector is an efficient, well-published method for determining lentivirus physical titer. The QuickTiter Lentivirus Quantitation Kits provide a convenient method of p24 antigen quantitation.

Recombinant HIV-1 p24 Core

7-07597 100µg Ask for price

Recombinant HIV-1 p24 Core

7-07598 500µg Ask for price

Recombinant HIV-1 p24 Core

7-07599 1000µg Ask for price

Recombinant HIV-1 p24 , 24kDa

7-07621 2µg Ask for price

Recombinant HIV-1 p24 , 24kDa

7-07622 10µg Ask for price

Recombinant HIV-1 p24 , 24kDa

7-07623 100µg Ask for price

HIV-1 p24 Recombinant Protein

53-341 0.01 mg
EUR 789.9
Description: HIV-1 p24 Recombinant Protein

HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa

00112-V-100ugvial 100ug/vial
EUR 150
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa

HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa

00113-V-100ugvial 100ug/vial
EUR 150
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa

HIV -2 env gp36 recombinant antigen

00179-V-01mg 0,1 mg
EUR 321
Description: HIV -2 env gp36 recombinant antigen. a.a 390 to a.a 702.

HIV -2 env gp36 recombinant antigen

00179-V-1000ug 1000 ug
EUR 1539
Description: HIV -2 env gp36 recombinant antigen. a.a 390 to a.a 702.

HIV-1 tat recombinant antigen full length 15 kDa

00110-V-100ugvial 100ug/vial
EUR 150
Description: HIV-1 tat recombinant antigen full length 15 kDa

HIV type 1 P24 [GST]

DAG1516 100 µg
EUR 774

HIV type 1 P24 [His]

DAG1518 100 µg
EUR 774

HIV type 1 P24 [His]

DAG1799 50 ug
EUR 2017.2

HIV type 1 P24 [His]

DAG2375 100 µg
EUR 868.8

HIV type 1 P24 [His]

DAG2377 100 µg
EUR 868.8

HIV-1 p24 Immune Complex Dissociation Kit

Z7040009 1 kit
EUR 122

HIV type 1 p24 [FITC]

DAGH004 50 Tests
EUR 1112.4

HTLV-I p24 core recombinant antigen

00204-V-01mg 0,1 mg
EUR 321
Description: HLTV-I p24 core recombinant antigen.

HTLV-I p24 core recombinant antigen

00204-V-1000ug 1000 ug
EUR 1539
Description: HLTV-I p24 core recombinant antigen.

HLTV-I p24 core recombinant antigen.

00204-V-100ugvial 100 ug/vial
EUR 150
Description: HLTV-I p24 core recombinant antigen.

HIV type 1 P24 [Biotin]

DAG1519 100 µg
EUR 972

Feline Immunodeficiency Virus p24 gag Antigen (FIV p24 gag) Antibody

abx413943-025mg 0.25 mg
EUR 811.2

HIV-1 gag p17, p24 Protein

20-abx260277
  • EUR 1062.00
  • EUR 410.40
  • EUR 1930.80
  • 0.5 mg
  • 100 ug
  • 1 mg

HIV-1 p24, 24 kDa Protein

20-abx263118
  • EUR 1562.40
  • EUR 393.60
  • EUR 276.00
  • 100 ug
  • 10 ug
  • 2 µg

Recombinant HIV-1 gag p17, p24

7-07675 100µg Ask for price

Recombinant HIV-1 gag p17, p24

7-07676 500µg Ask for price

Recombinant HIV-1 gag p17, p24

7-07677 1000µg Ask for price

Felis p27 core antigen ELISA Kit

ELA-E1491FELA-E 96 Tests
EUR 1113.6

HIV-1 p24 Core, Sf9 Protein

20-abx260012
  • EUR 2815.20
  • EUR 493.20
  • EUR 276.00
  • 100 ug
  • 10 ug
  • 2 µg

Mouse Monoclonal Anti- HIV-1 p24 IgG

AB-15210 100 ug
EUR 416.4

Toxoplasma gondii P24 (GRA1) recombinant antigen

00207-V-01mg 0,1 mg
EUR 321
Description: Toxoplasma gondii P24 (GRA1) recombinant antigen

Toxoplasma gondii P24 (GRA1) recombinant antigen

00207-V-1000ug 1000 ug
EUR 1539
Description: Toxoplasma gondii P24 (GRA1) recombinant antigen

Toxoplasma gondii P24 (GRA1) recombinant antigen

00207-V-100ugvial 100ug/vial
EUR 150
Description: Toxoplasma gondii P24 (GRA1) recombinant antigen

HIV-1 gp120 and gp41 Chimeric Antigen (16 kDa, Capture)

DAGF-220 1mg
EUR 817.2

HIV-1 gp120 and gp41 Chimeric Antigen (8 kDa, Capture)

DAGF-222 1mg
EUR 817.2

HIV-1 gp120 and gp41 Chimeric Antigen (45 kDa, Capture)

DAGF-224 1mg
EUR 817.2

Recombinant HIV-1 p24 His Tag

7-07606 5µg Ask for price

Recombinant HIV-1 p24 His Tag

7-07607 20µg Ask for price

Recombinant HIV-1 p24 His Tag

7-07608 1mg Ask for price

HIV-1 gp120 and gp41 Chimeric Antigen (43 kDa, Detection)

DAGF-223 1mg
EUR 817.2

Recombinant HIV-1 p24 Core, Sf9

7-07600 2µg Ask for price

Recombinant HIV-1 p24 Core, Sf9

7-07601 10µg Ask for price

Recombinant HIV-1 p24 Core, Sf9

7-07602 100µg Ask for price

HIV-1 p24, Biotin Labeled Protein

20-abx260358
  • EUR 1496.40
  • EUR 560.40
  • EUR 2364.00
  • 0.5 mg
  • 100 ug
  • 1 mg

Recombinant Human Immunodeficiency Virus Type 1 Antigen, P24

DAG515 1mg
EUR 1444.8

p24-HIV(p24/661) Antibody

BNC470661-100 100uL
EUR 238.8
Description: Primary antibody against p24-HIV(p24/661), CF647 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC470661-500 500uL
EUR 652.8
Description: Primary antibody against p24-HIV(p24/661), CF647 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC550661-100 100uL
EUR 238.8
Description: Primary antibody against p24-HIV(p24/661), CF555 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC550661-500 500uL
EUR 652.8
Description: Primary antibody against p24-HIV(p24/661), CF555 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC400661-100 100uL
EUR 238.8
Description: Primary antibody against p24-HIV(p24/661), CF640R conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC400661-500 500uL
EUR 652.8
Description: Primary antibody against p24-HIV(p24/661), CF640R conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC430661-100 100uL
EUR 238.8
Description: Primary antibody against p24-HIV(p24/661), CF543 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC430661-500 500uL
EUR 652.8
Description: Primary antibody against p24-HIV(p24/661), CF543 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC800661-100 100uL
EUR 238.8
Description: Primary antibody against p24-HIV(p24/661), CF680 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC800661-500 500uL
EUR 652.8
Description: Primary antibody against p24-HIV(p24/661), CF680 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC810661-100 100uL
EUR 238.8
Description: Primary antibody against p24-HIV(p24/661), CF680R conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC810661-500 500uL
EUR 652.8
Description: Primary antibody against p24-HIV(p24/661), CF680R conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC610661-100 100uL
EUR 238.8
Description: Primary antibody against p24-HIV(p24/661), CF660R conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC610661-500 500uL
EUR 652.8
Description: Primary antibody against p24-HIV(p24/661), CF660R conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNUM0661-50 50uL
EUR 474
Description: Primary antibody against p24-HIV(p24/661), 1mg/mL

p24-HIV(p24/661) Antibody

BNCB0661-100 100uL
EUR 238.8
Description: Primary antibody against p24-HIV(p24/661), Biotin conjugate, Concentration: 0.1mg/mL

 

Related articles

mutationdetection

Identification of key gene modules and pathways of human platelet transcriptome

Identification of key gene modules and pathways of human platelet transcriptome in acute myocardial infarction sufferers by way of co-expression community Acute myocardial infarction (AMI) critically threatens human life. On this examine we aimed to systemically analyze the perform of key gene modules in human platelets in AMI. We used weighted gene co-expression community evaluation (WGCNA) […]

Learn More
mutationdetection

putative novel insertion sequence elements in prokaryotic genomes

digIS: in direction of detecting distant and putative novel insertion sequence components in prokaryotic genomes Background: The insertion sequence components (IS components) symbolize the smallest and probably the most plentiful cell components in prokaryotic genomes. It has been proven that they play a big position in genome group and evolution. To higher perceive their perform within the […]

Learn More
mutationdetection

signatures of positive selection in cytochrome b gene

Trying to find signatures of optimistic choice in cytochrome b gene related to subterranean life-style in fast-evolving arvicolines (Arvicolinae, Cricetidae, Rodentia) Background: Mitochondrial genes encode proteins concerned in oxidative phosphorylation. Variations in life-style and ecological area of interest could be immediately mirrored in metabolic efficiency. Subterranean rodents characterize a very good mannequin for testing hypotheses on adaptive evolution […]

Learn More

Leave a Reply

Your email address will not be published. Required fields are marked *